-
If medical abortion using mifepristone (Mifeprex, Danco Group) and misoprostol is offered at your facility, be sure to review a new study that asserts the safety of a particular mifepristone/misoprostol regimen.
-
Clinicians now have an approved indication in hand for use of the levonorgestrel intrauterine system Mirena (LNG IUS, Mirena, Bayer HealthCare Pharmaceuticals; Wayne, NJ), to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention.
-
Two new actions from the Food and Drug Administration (FDA) will impact your practice.
-
Check the records of women who are scheduled to return to your facility for a contraceptive refill or annual well woman exam. Are you seeing empty spots in the schedule?
-
Update your clinical practice; make your plans now for the following 2010 conferences:
-
Women in the United States now account for more than one-quarter of all new HIV/AIDS diagnoses.
-
Good news for patients at your clinic: The second-generation FC2 Female Condom is available for purchase in the United States, which gives American women a nonlatex, female-controlled option in disease protection.
-
Headaches are one of the most common problems of patients presenting to primary care physicians. Workup and management can be both frustrating and demanding.
-
An oral direct thrombin inhibitor, dabigatran, prevents ischemic strokes in patients with atrial fibrillation, with fewer hemorrhagic strokes as compared to warfarin.
-
In a delayed-start trial of rasagiline in early Parkinson's disease, 1 mg rasagiline daily met all three predetermined endpoints consistent with disease modification. However, a dose of 2 mg daily did not meet all endpoints, complicating interpretation.